<ul><li>Israeli AI biotech startup SpotitEarly has raised $20.3 million to scale its noninvasive breath test for cancer detection in the U.S.</li><li>SpotitEarly uses AI and canines to analyze volatile organic compounds in exhaled breath to identify cancer biomarkers.</li><li>The company's LUCID platform integrates AI to process breath samples and has shown 94% accuracy in a clinical trial of 1,200 people.</li><li>SpotitEarly plans to make home testing kits available by 2026 in the U.S. and has appointed U.S.-based advisers to its scientific board.</li></ul>

AI biotech firm SpotitEarly raises $20.3M to scale noninvasive cancer detection in US

Discover more